In hepatocellular carcinoma, particularly in alcohol-related liver disease, IL-17–mediated activation of hepatocytes and macrophages drives inflammation and tumor development, while pathway inhibition attenuates these effects (Ma et al., 2020). This evidence concerns the gene IL17A and hepatocellular carcinoma.